TL;DR: US drugmaker Eli Lilly will invest more than $1 billion in India to expand manufacturing and set up a new hub in Hyderabad, creating jobs and boosting production of medicines like Mounjaro.
Investment and Expansion
Major Investment:
On October 6, 2025, Eli Lilly announced it will invest over $1 billion in India over the next few years to expand its manufacturing capacity and supply chain.
New Hyderabad Hub:
A manufacturing and quality hub will be set up in Hyderabad, serving as the oversight center for Lilly’s contract manufacturing network across India.
Job Creation:
Hiring will begin immediately for roles in engineering, chemistry, analytical science, quality control, and management.
Medicines Focus:
The investment will support production of key medicines for diabetes, obesity (including Mounjaro), Alzheimer’s, cancer, and autoimmune diseases.
Existing Presence in India:
Eli Lilly already operates in Gurugram, Bengaluru, and Hyderabad, employing over 1,400 professionals in research and development, IT, and data analytics.
Government Support:
Telangana Chief Minister A. Revanth Reddy welcomed the move, calling it a sign of Hyderabad’s role as a healthcare innovation hub.
Global Strategy:
Since 2020, Eli Lilly has invested over $55 billion globally to expand manufacturing in response to high demand for GLP-1 drugs like Mounjaro and Zepbound.